Skip to end of metadata
Go to start of metadata

The Center of Excellence in Immunology (CEI) is one of 5 Centers of Excellence within the NCI Intramural Research Program (IRP). These Centers are multi-disciplinary venues that generate connections among diverse intellectual, financial, and physical resources within the IRP to help develop new initiatives, projects, and collaborations that reduce the burden of cancer.

Mission

The Mission of the Center of Excellence in Immunology is to foster discovery, development, and delivery of novel immunologic approaches for the prevention and treatment of cancer and cancer-associated viral diseases.

Objectives

  • Provide a format to integrate the diverse fields within immunology and facilitate translation of basic research discoveries into successful treatments
  • Serve as a distinctive think tank
  • Blend basic and clinical scientific expertise and perspectives
  • Merge disciplines and promote new perspectives
  • Provide attractive partnership options for academia and pharmaceutical companies
  • Promote interaction of immunologists in the intra- and extramural communities

 

Selected Activities

  • Save the Date for the 2019 Immunology Symposium "Cancer and Inflammation: from Micro to Macro" which will be held on October 17-18th on the Bethesda campus of the NIH. Information on the program will soon be available.
  • The Immunology and Immunotherapy Seminar Series
  • Collaborations with the Center for Human Immunology
  • Collaborations with the Cancer Immunotherapy Network (CITN)
  • Partnerships with the Society for the Immunotherapy of Cancer (SITC)
  • Collaborations with Biotech and Pharma


Selected Recent Publications

Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression.  Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, Patel NL, Palmieri EM, Weiss JM, Lee JM, Annunziata CM, Rouault TA, Durum SK, McVicar DW. Nat Commun. Nov 2018

miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity. Ishii H, Vodnala SK, Achyut BR, So JY, Hollander MC, Greten TF, Lal A, Yang L. Nat Commun. July 2018

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.  Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA.  Nat Med. Jun 2018

Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation. Balagopalan L, Yi J, Nguyen T, McIntire KM, Harned AS, Narayan K, Samelson LE. Nat Commun. May 2018

Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF. Science. May 2018

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB. Lancet Oncol. Jan 2018

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress RE.  Lancet Haematol. Jan 2018

Peritoneal tissue-resident macrophages are metabolically poised to engage microbes using tissue-niche fuels.  Davies LC, Rice CM, Palmieri EM, Taylor PR, Kuhns DB, McVicar DW. Nat Commun. Dec 2017

T-bet-dependent NKp46+ innate lymphoid cells regulate the onset of TH17-induced neuroinflammation. Kwong B, Rua R, Gao Y, Flickinger J Jr, Wang Y, Kruhlak MJ, Zhu J, Vivier E, McGavern DB, Lazarevic V.  Nature Immunology. Oct 2017

Identification of lineage-specifying cytokines that signal all CD8+-cytotoxic-lineage-fate 'decisions' in the thymus. Etzensperger R, Kadakia T, Tai X, Alag A, Guinter TI, Egawa T, Erman B, Singer A. Nat Immunol. Nov 2017

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US.Lancet Oncol. June 2017

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Science. April 2017

Identification of essential genes for cancer immunotherapy.   Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP. Nature. Aug 2017.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial Christopher R Heery, Geraldine O’Sullivan-Coyne, Ravi A Madan, Lisa Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L Marté, Lauren M Lepone, Renee N Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin Chin, Jeffrey Schlom, James L Gulley  Lancet Oncology, May 2017

Avelumab for patients with previously treated metastatic recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial James L Gulley, Arun Rajan, David R Spigel, Nicholas Iannotti, Jason Chandler, Deborah J L Wong, Joseph Leach, W Jeff Edenfield, Ding Wang, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, Jean-Marie Cuillerot, Karen Kelly  Lancet Oncology, May 2017

 

 

 

 

Last updated by Linnekin, Diana (NIH/NCI) [E] on Jan 10, 2019